CymaBay Therapeutics, Inc. CBAY
At closeMar 21, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 3.73B
- Revenue (ttm)
- 31.07M
- Shares out
- 114.78M
- Forward P/E
- -30.93
- Volume
- 8.35M
- Open
- 32.49
- Previous close
- 32.48
- Day's range
- 32.48 – 32.50
- Beta
- 0.32
- Analysts
- Hold
- Price target
- 32.50 (+0.1%)
- Earnings date
- Feb 28, 2024
2Y +29.33 (+931.11%)
Key statistics
- Enterprise value
- 3.45B
- PEG ratio
- 0.00
- Price / sales
- 119.98
- Price / book
- 12.65
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -54.82M
- Total cash
- 394.26M
- Total debt
- 114.49M
- Return on equity
- -64.17%
- Short % of float
- 5.88%
- 50-day average
- 29.11
- 200-day average
- 19.07
Analyst view
Consensus: hold
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 28, 2024
Expected Feb 28, 2024. Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 28, 2024 | Dec 1, 2023 | -0.32 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -0.30 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.21 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.16 | — | — | — |
| Mar 16, 2023 | Dec 1, 2022 | -0.30 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2023 | UBS | main | Buy | Buy |
| Sep 7, 2023 | B. Riley Securities | main | Buy | Buy |
| Sep 7, 2023 | BTIG | main | Buy | Buy |
| Sep 7, 2023 | Raymond James | main | Strong Buy | Strong Buy |
| Sep 6, 2023 | Raymond James | main | Strong Buy | Strong Buy |
| Sep 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cymabay.com
News
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board 
Gilead Sciences Announces Completion of Acquisition of CymaBay 
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis 
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates 
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update 
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis 
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY 
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion 
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
Your note
Sign in to keep a note on CBAY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICKINSON-EASON KLARA A | Officer | Stock Award(Grant) | Jan 23, 2024 | 21,000 |
| DORLING JANET | Director | Sale | Feb 11, 2024 | 0 |
| EMSTER KURT VON | Director | Sale | Sep 28, 2023 | 108,406 |
| GOLDFISCHER CARL S | Director | Sale | Feb 6, 2019 | 0 |
| KIM DENNIS D | Officer | Sale | Apr 16, 2023 | 20,000 |
| MCWHERTER CHARLES A | Officer | Stock Award(Grant) | Jan 23, 2024 | 46,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.33% | 10,300,000 | 112.78M | Jun 29, 2023 |
| Janus Henderson Group PLC | 7.02% | 7,746,587 | 84.83M | Jun 29, 2023 |
| Blackrock Inc. | 6.80% | 7,504,670 | 82.18M | Jun 29, 2023 |
| Vanguard Group Inc | 4.67% | 5,148,880 | 56.38M | Jun 29, 2023 |
| Octagon Capital Advisors LP | 4.14% | 4,570,918 | 50.05M | Jun 29, 2023 |
| Adage Capital Partners GP L.L.C. | 3.99% | 4,401,292 | 48.19M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.71% | 2,986,738 | 32.70M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.03% | 2,235,209 | 30.73M | Aug 30, 2023 |
| Janus Henderson Global Life Sciences Fund | 1.51% | 1,663,467 | 18.21M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.13% | 1,252,335 | 13.71M | Jun 29, 2023 |
| Janus Henderson Triton Fund | 1.08% | 1,193,958 | 13.07M | Jun 29, 2023 |
| PGIM Jennison Health Sciences Fd | 1.02% | 1,122,754 | 15.44M | Aug 30, 2023 |